赛百诺公司科技专家委员会，是赛百诺加强公司科技研发力量和建设专家“智库”的一个重要举措。委员会是在董事会领导下，对公司医药投资项目进行经济技术分析的内部咨询机构，负责对公司医药方面中长期发展规划、新产品开发方向、拟开发新产品的立项考察、公司日常研究开发工作等提出建议和指导意见。
Sibiono Science and Technology Experts Committee (SSTEC) is major administrative measure for the strengthening of S&T basis and the maintenance of an expert panel within the company. It is under the guidance of the Board of Directors for suggesting and guiding investment analysis, medium to long term development planning, new drug development possibility, pathways and their execution,including daily R&D routine.
孙燕院士：中国工程院院士。现任中国医学科学院协和医科大学肿瘤医院临床药理基地和国家抗肿瘤药GCP中心主任、世界卫生组织癌症专家顾问委员会委员、亚洲临床肿瘤学会副主席。
Yan Sun Member of Chinese Academy of Engineering (Acad memb), and Chinese Academy ofMedical Science-Peking Union Medical College & ‘National Anti-tumor Drug GCP Center’, member of ‘Cancer Expert Advisory Board’ of WHO, deputy president of ‘Asia Clinical Oncology Society’(ACOS).
吴祖泽院士：中国科学院院士，是我国干细胞研究、血液研究、基因治疗药物研究等领域的主要创始人之一，领衔研发的数个治疗肿瘤和心血管疾病的基因治疗新药已进入各期临床试验，原军事医学科学院院长。
ZuZe Wu (Acad memb) He is a pioneer in stem cell, hematology, gene therapy in China. Developer of several new gene therapy drugs for tumor and cardiovascular diseases, and are in the process of different clinical trials. Past president of the Academy of Military Sciences.
曾益新院士：中国科学院院士，主要从事肿瘤发病机理及肿瘤基因治疗研究。现任中山大学附属肿瘤医院院长、肿瘤防治中心主任、肿瘤研究所所长，赛百诺公司科技专家委员会主任委员。
Yi Xin (Acad memb) He engages in the study of pathogenesis and gene therapy of tumor. The president of the Sun Yat–Sen Univ. Cancer Center, director of Cancer Prevention Center, head of Tumor Research Institute and chief of Committee Member of Sibiono ‘S&T Expert Panel’
魏于全院士：中国科学院院士，主要从事肿瘤发病机理及肿瘤基因治疗研究。现任四川大学副校长、生物治疗国家重点实验室主任、中华医学会副会长。
YuQuan Wei (Acad memb) He focuses on the pathogenesis and gene therapy. Prof Wei is the vice-president of Sichuan Univ., head of National Key Lab of Biotherapy for Cancer, vice-chairman of the Chinese Medical Assoc.
黄文林教授：教授，我国著名的病毒学专家，其研发的肿瘤基因治疗药物“重组人内皮抑素腺病毒注射液”已进入II期临床试验。现任中山大学肿瘤医院生物治疗中心主任、《癌症》杂志副主编。
Wenlin Huang (professor) is a prominent virologist. He leads the tumor gene therapy ‘recombinant human endostatin adenovirus injection’ which has entered Phase II clinical trial. Now he is Chief of biotherapy at the Sun Yat-sen Univ. Tumor Hospital and assoc. editor of the journal’Cancer’.
高贵：医学博士， 1998年赴美国留学和工作，获美国佛罗里达州南佛罗里达大学公共卫生学院临床实验和生物统计学硕士学位。曾先后在Moffitt癌症研究中心等专业机构从事基础研究、药物研发、临床实验，及药物FDA注册和生物统计学工作。
Gui Gao (MD, professor; MS, biostatistics). He earned his MS degree (1998) in clinical biostatistics at the University of S. Florida, College of Public Health. He accumulated his expertise from Moffitt Cancer Research Center (biostatistics), Axiom Worldwide, BioStat International, Research Pharmaceutical Services in areas of clinical pharmacology R&D, FDA drug registration and related biostatistics work.
张维维：美国阿拉巴马大学分子生物学博士，在基因治疗及基因表达载体研究与应用领域成就显著， l992年就在美国率先研制出第一代抗肿瘤腺病毒的基因治疗产品(Ad5-p53)，是赛百诺公司主要奠基人。
WeiWei Zhang (MD; PhD in molecular biology, Alabama) He was instrumental in the introduction of first generation adenovirus gene therapy drug: ‘Ad5-p53’ and was the principal founder of Sibiono.
张书元：博士英国Surrey 大学细胞工程博士，世界知名的GMP设计专家，在病毒载体传递基因，基因载体疫苗和基因修饰的细胞载体方面有超过17年的产业化经验。
S Y Zhang (PhD, Surry) He was trained in cell engineering and has been working with viral vector delivery of gene, viral vector vaccine and gene-modified cell vectorfor nearly 2 decades.He also led the gene vector application group at a FDA-complied lab atIntrogen Inc. on gene vector application team. He is a well-known GMP designer.
Diosdado S. Bautista：麦克马斯特大学医学博士（1990），现任Modecs Genetics Inc (加拿大安大略省多伦多市)总裁兼首席执行官、联合创始人。曾任Norgen Biotek Corp. (Canada) Vice-President for R&D 研发副总裁(1999-2005)。
Diosdado S. Bautista (MD,McMaster,1990) Director, CEO & co-founder of Modecs Genetics, past vice-president R&D of Norgen Biotek Corp(1999-2005).
